

# Devices for the transport and microbiological detection of *Neisseria gonorrhoeae* in sexual health clinic samples: a prospective comparative study

International Journal of STD & AIDS  
2022, Vol. 0(0) 1–6  
© The Author(s) 2022  
Article reuse guidelines:  
[sagepub.com/journals-permissions](https://sagepub.com/journals-permissions)  
DOI: 10.1177/09564624221136640  
[journals.sagepub.com/home/std](https://journals.sagepub.com/home/std)  
**SAGE**

Leon Jonker<sup>1</sup>  and Matt Phillips<sup>2</sup>

## Abstract

**Background:** Propagation and microbiological detection of *N. gonorrhoeae* can be challenging due to the fastidious nature of the bacterium outside the human host environment. Different sample transport options were evaluated in order to address this issue.

**Methods:** Symptomatic and high-risk patients consented to take part. Standard practice in clinics involve using a guanine and cytosine selective (GC) plate for transport and incubation. Other devices were assessed in two different studies. MWE's Sigma VCM™-a transport device for use between clinic and laboratory-was used in one study ( $n = 166$ ). In the other, ( $n = 102$ ), Biomed's InTray™ plates were used, which can be used for both initial transport and incubation at the destination laboratory.

**Results:** In the Sigma VCM™ study, positive results were obtained for 14% (Sigma VCM™), 21% (GC plates); the distribution of outcomes did not significantly differ between the two microbiological sampling methods ( $p$ -value 0.09, Chi-squared test). Concerning the InTray™ sub-study, *N. gonorrhoeae* was detected in 9% (InTray™), 13% (GC plating) of cases respectively, with again no significant difference between the microbiological sampling methods ( $p$ -value 0.25). Regression analysis identified a significant association between *N. gonorrhoeae* detection and male patients, absence of dysuria and previous gonorrhoea infection.

**Conclusion:** No significant difference in rate of microbiological detection of *N. gonorrhoeae* could be detected between different transport devices in a sexual health clinic setting. Performance appraisal of transport devices for bacterial sexually transmitted infection can inform practitioners' options regarding said devices.

## Keywords

Gonorrhea (*Neisseria gonorrhoeae*), bacterial disease, Europe, location, diagnosis, other

Date received: 3 May 2022; revised: 11 October 2022; accepted: 17 October 2022

## Background

Of approximately 500,000 diagnoses of sexually transmitted infections (STIs) in England per annum, over 40,000 are gonorrhoea cases.<sup>1</sup> The bacterium *N. gonorrhoeae* causes an infection of the lower genital tract, and undetected or inadequately treated gonorrhoea can cause serious reproductive health consequences such as epididymitis and prostatitis in men and pelvic inflammatory disease, infertility and ectopic pregnancy in women.<sup>1–5</sup> Additionally, the emergence of drug resistant gonococcal strains have increased rapidly in recent years, thereby reducing treatment options and causing a threat to public health.<sup>4</sup> Routine diagnostic testing is widely recommended to slow the spread of resistant gonorrhoea.<sup>2,6</sup> The

incidence of gonorrhoea may be underestimated in some European countries due to suboptimal access to laboratory facilities for microbiological testing and associated antibiotic resistance profiling and/or confirmation of

<sup>1</sup> Science & Innovation Manager, R&D Department, North Cumbria Integrated Care NHS Foundation Trust, Penrith, UK

<sup>2</sup> Sexual Health Consultant, Sexual Health Services, North Cumbria Integrated Care NHS Foundation Trust, Carlisle, UK

## Corresponding author:

Leon Jonker, Science & Innovation Manager, R&D Department, North Cumbria Integrated Care NHS Foundation Trust, Penrith, CA 11 8HX, UK.  
Email: [leon.jonker@ncic.nhs.uk](mailto:leon.jonker@ncic.nhs.uk)

nucleic acid amplification testing (NAAT)-positive samples.<sup>6</sup>

Diagnosis of gonorrhoea is confirmed by the detection of *N. gonorrhoeae* at an infected site. The methods used to diagnose gonorrhoea are influenced by the clinical setting, storage and transport system to the laboratory, which in developed countries typically involves a combination of microbiological incubation culture and NAAT. NAATs are recommended for both symptomatic and asymptomatic infections in men and women and achieve sensitivity of >90%.<sup>2,3</sup> A microbiological diagnostic evaluation has the additional benefit of antimicrobial susceptibility testing allowing for early detection of antibiotic resistance.

*N. gonorrhoeae* bacteria are technically difficult to preserve and recover from clinical specimens.<sup>7</sup> Recovery rates of *N. gonorrhoeae* also differ per anatomical site; it is particularly challenging to diagnose gonorrhoea from extragenital site samples.<sup>8</sup> For developing countries, the technical and cost challenges around microbiological diagnosis for *N. gonorrhoeae* may contribute to the use of a syndromic approach to gonorrhoea management rather than using a microbiological approach.<sup>9</sup> In order to achieve effective laboratory diagnosis - bearing in mind the organism's fastidious nature - it is desirable to optimise collection and transport of samples.<sup>10,11</sup> Across two separate evaluation sub-studies, the overall aim was to assess the effectiveness of the novel InTray™ GC system (Biomed Diagnostics) and Sigma VCM™ transport medium (Medical Wire Equipment) compared to the current standard method of plating onto standard agar plates in order to detect *N. gonorrhoeae* in microbial samples from sexual health clinics.

## Methods

### Patients and study design

Two separate, consecutive, prospective evaluative studies were conducted at two clinic locations within one National Health Service (NHS) Trust in England between 2018 and 2021. The performance of MWE's Sigma VCM™ was initially assessed (registered under clinical trial registry number ISRCTN55795067), followed by a subsequent study appraising the Biomed InTray™ product (trial registry reference ISRCTN16307168). This two-stage approach was taken to avoid excessive tissue sampling (swabbing) on the same patient. The methodology, such as patient eligibility, in addition to processing and analysis of standard clinical samples (GC plate and NAAT sample), was identical for each sub-study and is described below. Eligibility included: patient aged 18 years or older, capacity to provide written, informed consent and [a] presentation to a sexual health clinic with symptom(s) that could be indicative of gonorrhoea infection (i.e. presence of urethral or vaginal discharge and/or dysuria) or [b] recent medical history and risk

factors that, in the opinion of the treating clinician, warranted investigation for gonorrhoea infection. Full written informed consent was obtained from all study subjects by sexual health nursing staff in a clinic setting. The same staff also collated the study related outcome measures and demographic information, most of this being routinely collated clinical data.

### Medical devices and diagnostics

Microbiological testing was the diagnostic test appraised in this study, meaning the growth of bacteria on a selective medium agar plate;<sup>12</sup> the GC plate for standard practice was Oxoid Lysed GC Selective agar with VCAT supplement (Thermo Fisher Scientific). Sigma VCM™ samples transferred onto such plates in the laboratory, whereas InTray™ plate samples did not have to be transferred. However, as part of standard practice in the laboratory, an oxidase test, a Gram stain for positive colonies and confirmatory biochemical API® *Neisseria* and *Haemophilus* test were also performed. Once received by the central laboratory, all GC plates were incubated at 37°C and 5% CO<sub>2</sub> for a further 48 h, with separate NAAT testing taking place in parallel in the same laboratory. A separate swab was taken for NAAT testing, using AMPLICOR CT/NG Specimen Preparation Kit (Roche Diagnostics) and then EuroClone® dual testing kit for both *N. gonorrhoeae* and *Chlamydia trachomatis* on Roche Diagnostics COBAS® system.

As mentioned, patient recruitment took place at two clinic locations. Due to a difference in distance to the central laboratory, there was a subsequent difference in processing and transport of samples. At clinic location A ("direct incubation" method), the GC plates were incubated directly at 37°C until they were collected and transferred in individual, sealed bags (containing CO<sub>2</sub> generators) to the central laboratory. At clinic location B ("indirect incubation" method), the streaked GC plates were kept at room temperature in a CO<sub>2</sub>-rich environment in a gas jar followed by collection and transfer to the central laboratory.

Medical Wire Equipment (Corsham, United Kingdom) markets Sigma VCM™ (MW911S) which meets the Clinical and Laboratory Standards Institute requirements for Quality Control of Microbiological Transport Systems concerning the recovery of *N. gonorrhoeae*. This is a small vial containing 1.0 mL liquid Amies Transport Medium and contains a cellular foam bud for sampling. At both clinic locations (A and B), the Sigma VCM™ samples were kept at ambient temperature until arrival at the central laboratory where the foam bud was streaked onto a standard GC plate and incubated as per normal procedure.

BioMed Diagnostics (White City, United States) offers InTray™, a microbiology sample collection, transport, and culture in vitro device designed for simultaneous detection and observation of *N. gonorrhoeae*. The InTray™ system consists of an outer, re-sealable label with a clear window

**Table 1.** Overview of demographics for each of the two studies assessing transport device for microbiological *N. gonorrhoeae* detection.

	Study assessing sigma VCM™ (consented <i>n</i> = 170)	Study assessing InTray™ (consented <i>n</i> = 102)
Public study registration number	ISRCTN55795067	ISRCTN16307168
Male/Female, <i>n</i> (%)	94 (55%)/76 (45%)	40 (39%)/62 (61%)
Age, mean age in years	29	28
Presenting with dysuria, <i>n</i> yes (%)	103 (61%)	62 (61%)
Presenting with discharge, <i>n</i> yes (%)	84 (49%)	61 (60%)
History of gonorrhoea infection	34 (20%)	21 (21%)
Condom use: never/sometimes/always, <i>n</i> (%)	103 (61%)/59 (35%)/8 (5%)	67 (66%)/33 (32%)/2 (2%)
Samples present for both GC plating and investigational device, <i>n</i> (%)	166 (98%)	101 (99%)
NAAT result present, <i>n</i> (%)	163 (96%)	80 (78%)

covering the media, which creates an airtight seal over the 2" diameter surface. An incorporated CO<sub>2</sub> tablet can be activated to create a ~7% CO<sub>2</sub> environment. Similar to the GC plates, InTray™ samples were incubated directly at clinic location A, and at clinical location B they were left at room temperature until arrival at the central laboratory.

### Outcome measures and analysis

The primary outcome was to determine the respective microbiological detection rates of *N. gonorrhoea* for Sigma VCM™ and InTray™ compared to current plating practise (GC medium). The secondary outcome was to compare NAAT molecular diagnostics. Sample size calculation was based on a hypothetical 20% absolute difference in positive cases between opposite transport devices, equating to an effect size of 0.4, which translates to a minimum of 48 study subjects when a 80% power and a *p*-value of 0.05 is defined as a significant difference using Chi-squared test as the inferential statistical test. For samples where a NAAT result was available in addition to microbiological results for standard and investigational transport device, Kappa concordance levels were determined. Since they were not paired, Kappa concordance could not be appraised for Sigma VCM™ versus InTray™. Binary logistic regression was conducted using NAAT and GC plate results as respective dependents, since more samples were available for these methods compared to the two new transport devices tested. Variables included in the model concerned data collated per standard clinical practice (see Table 3). Data was first collated with Microsoft Excel, before analysis with IBM SPSS v24 statistics software.

## Results

Table 1 provides an overview of the demographics and respective study details. Initially, the relative performance

of GC plating was compared to the two other microbiological transport devices; although GC plates and InTray™ both also served as the eventual incubation device. In the Sigma VCM™ sub-study, considering only those GC plate and NAAT samples that were processed alongside the Sigma VCM™ samples, positive results were obtained for 14% (Sigma VCM™), 21% (GC plates), and 23% (NAAT) of cases. Kappa concordance rates were 0.56 (Sigma VCM™ vs NAAT), and 0.87 (GC plates vs NAAT). In the InTray™ sub-study again, considering only sub-study specific GC plate and NAAT samples, *N. gonorrhoeae* was detected in 9% (InTray™), 13% (GC plating) and 20% (NAAT) of cases respectively; Kappa concordance was 0.52 (InTray™ vs. NAAT) and 0.60 (GC plating vs NAAT). Table 2 summarises the results specifically for the microbiological devices. Despite higher detection rates achieved with GC plates compared to both Sigma VCM™ and InTray™, a statistically significant difference is not observed through Chi-squared testing. Table 3 shows the comparison of NAAT against the three transport devices. On this occasion, the GC plate and NAAT samples from both sub-studies could be combined for analysis because they are paired samples (i.e. sample taken from same patient). GC plate samples match the NAAT sample results more closely than those from Sigma VCM™ and InTray™; with Sigma VCM™ result distribution being significantly different from NAAT. The Kappa concordance levels for both Sigma VCM™ (0.57) and InTray™ (0.52) against NAAT results are lower than seen with GC plate samples (0.79).

Regression analysis identifies a significant association between *N. gonorrhoeae* detection and male patients, absence of dysuria and positive history of previous gonorrhoea infection (see Table 4). This remains the case when either a positive GC plate result or a positive NAAT result is considered the dependent outcome. However, only in cases of a positive result with GC plating does the presence of genital discharge show a significant association. In both

**Table 2.** Overview of test results for microbiological *N. gonorrhoeae* detection.

GC plate result	Sigma VCM™ (n = 166)		Intray™ (n = 101)	
	Positive, n (%)	Negative, n (%)	Positive, n (%)	Negative, n (%)
Positive, n (%)	22 (13%)	14 (8%)	7 (7%)	6 (6%)
Negative, n (%)	2 (1%)	128 (77%)	1 (1%)	87 (86%)
Chi-squared test for % positives per test, p-value	0.09		0.25	
Kappa concordance, value (p-value)	0.68 (<0.001)		0.59 (<0.001)	

**Table 3.** Comparison of microbiological versus molecular *N. gonorrhoeae* diagnostics.

NAAT result	GC plate <sup>a</sup> (n = 240)		Sigma VCM™ (n = 162)		Intray™ (n = 80)	
	Positive, n (%)	Negative, n (%)	Positive, n (%)	Negative, n (%)	Positive, n (%)	Negative, n (%)
Positive, n (%)	39 (16%)	12 (5%)	19 (12%)	18 (11%)	7 (9%)	9 (11%)
Negative, n (%)	4 (2%)	185 (77%)	3 (2%)	122 (75%)	1 (1%)	63 (79%)
Chi-squared test for % positives per test, p-value	0.36		0.03		0.08	
Kappa concordance, value (p-value)	0.79 (<0.001)		0.57 (<0.001)		0.52 (<0.001)	

<sup>a</sup>Results of two separate studies combined (ie Sigma VCM™ and Intray™ study samples combined).

models, the considered variables explain a modest 15% (Nagelkerke  $R^2$  value) of the overall variation in dependent outcome.

## Discussion

The detection and recovery of *N. gonorrhoeae* bacteria from a patient's infection site allows for appropriate specific antimicrobial management and more widely, for public health surveillance since at present no vaccine is available. Propagation of *N. gonorrhoeae* in a laboratory environment is challenging; therefore optimal transfer from clinic to laboratory location is desired; particularly when sexual health clinics are at remote locations.<sup>2,13</sup> For the purpose of this study, two new microbiological transport devices (Sigma VCM™ and InTray™) were compared to direct inoculation of selective GC plates. Our results indicate that the latter device is non-inferior to the new devices and performs better when all three devices are compared to molecular NAAT testing.

This present “real-world” study differs from some other studies where the performance of different transport devices has been appraised through measurement of recovery rates, i.e. laboratory-based controlled application of *N. gonorrhoeae* onto either a medium plate or solution to then determine degree of bacterial growth after certain pause and subsequent incubation at 37°C.<sup>7,10,11</sup> In our study, the InTray™ device had the lowest concordance levels with both GC plating and NAAT results, but in a controlled experiment with different *N. gonorrhoeae* strains, recovery rates

with use of InTray™ showed less than 10% reduction in average log<sub>10</sub> Colony Forming Units (CFUs) per millilitre in a controlled experiment.<sup>14</sup> Two clinic-based studies on patient samples, both comparing InTray™ with modified Thayer-Martin agar plates, found a concordance of >0.85 but InTray™ being negative more often when the Thayer-Martin agar plate samples were positive.<sup>15,16</sup> To our knowledge, this is the first time results on relative performance of Sigma VCM™ to standard direct GC plating has been reported; based on outcome distribution and concordance with both standard GC plates and PCR, it does not outperform the others.

The overall performance of NAAT testing for *N. gonorrhoeae* is more sensitive than microbiological culture methods.<sup>17</sup> However, the results obtained in this present study indicate that NAAT cannot be used as a true gold standard to measure sensitivity and specificity performance because the NAAT result for eight patient samples was negative, yet the microbiology result was positive (a repeat NAAT result was not available in these instances). Previous studies have shown that discordance between culture and NAAT is more often seen in samples from female and asymptomatic patients.<sup>18,19</sup> Nonetheless, there have been occasions where the result(s) of either NAAT testing alone or a combined two-of-three positive tests (including mixture of culture results and NAAT results) have been used as a benchmark when appraising medical devices and tests for *N. gonorrhoeae*.<sup>16,17,20</sup> In addition to measuring concordance levels, our regression analysis shows an almost identical profile of what variables are associated with

**Table 4.** Binary logistic regression analysis of variables associated with positive *N. gonorrhoeae* result.

Variable (reference value first)	GC plate result as dependent (n = 269)		NAAT result as dependent (n = 243)	
	Odds ratio	p-value	Odds ratio	p-value
Age (continuous variable)	1.01	0.73	0.98	0.25
Sex (male/female)	0.41	0.02 <sup>a</sup>	0.40	0.02 <sup>a</sup>
Dysuria (absence/presence)	0.36	0.005 <sup>a</sup>	0.33	0.002 <sup>a</sup>
Discharge (absence/presence)	2.19	0.03 <sup>a</sup>	1.27	0.47
Sexual orientation (heterosexual/other)	0.51	0.24	1.01	0.99
Sexual contacts in last year (0, 1, ≥2)	1.70	0.20	0.91	0.81
Condom use (never, sometimes, always)	0.87	0.66	0.77	0.42
Previous gonorrhoea infection (no/yes)	2.63	0.02 <sup>a</sup>	2.84	0.01 <sup>a</sup>
Previous chlamydia infection (no/yes)	0.86	0.69	0.72	0.38
Nagelkerke R <sup>2</sup> value for regression model	0.15		0.15	

<sup>a</sup>Statistically significant at p-value < 0.05.

a positive *N. gonorrhoeae* GC plate result and NAAT result respectively. When further comparing GC culture and NAAT, the standout variable is the presence of discharge, which is significantly associated with GC culture only. This may possibly be due to the presence of a higher bacterial load, required to detect *N. gonorrhoeae* microbiologically, since this link has previously been demonstrated by others.<sup>21</sup>

A methodological advantage of this study (i.e. both sub-studies) is that it was conducted prospectively, and samples were obtained from patients presenting with symptoms of/high-risk history for gonorrhoea infection. One limitation of the study is that patients were enrolled at two locations where processing of the GC plates differs; at one location plates are incubated instantly prior to transport to the central laboratory whereas at the other location they are kept at ambient temperature prior to transport. This may be an issue since *N. gonorrhoeae* is sensitive to differing conditions.<sup>13,22</sup> The synchronised processing approach for GC plates and Inray™ and specific handling required for the Sigma VCM™ tubes—which cannot be incubated at 37°C and necessitate swabbing of the sample from tube to a GC plate-counter this drawback. Ultimately, it is this multi-location issue that prompted the appraisal of different transport devices. Despite a pragmatic approach to enrich for *N. gonorrhoeae* positive patients, the overall rate of positive tests was lower than anticipated and this affects the ability to draw conclusions on performance of the Inray™ cohort in particular. It is beyond doubt that, in this sample of patients, GC plating is non-inferior to the more cumbersome and expensive method of using the Sigma VCM™ tubes and more expensive Inray™ plate. Provided that there is awareness of potentially poorer recovery rates, particularly Sigma VCM™ has the advantage that the sample is stored in a locked tube and can potentially be transported over longer distances; this

may be suitable in developing countries with fewer microbiology laboratory facilities to enable antibiotic resistance testing. The challenge remains to find ways to improve microbiological *N. gonorrhoeae* recovery rates, and overall to establish a true, likely molecular technology-based, gold standard test. As part of meeting this challenge it is beneficial for both controlled and clinic-based assessments to be performed to get a clear picture of a device's (relative) performance. A microbiological device for *N. gonorrhoeae* transport and recovery will have to be practical and affordable to enable usage in different clinic settings.

### Acknowledgements

We are grateful to the patients at the participating sexual health clinics, and the sexual health department's clinical staff for contributing significantly to study subject recruitment.

### Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by Medical Wire Equipment and Biomed Diagnostics; each provided a non-restricted research grant through free-of-charge provision of medical devices, grant titles 'STRINGS study' and 'GONDOLA study' respectively.

### Contributorship

LJ, conceptualisation, investigation, methodology, formal analysis, writing-original draft; MP, conceptualisation, funding acquisition, chief investigator, study oversight, data collation, writing-reviewing and editing.



## Ethical standards

The authors assert that all procedures contributing to this work comply with the ethical standards of the relevant national and institutional guidelines on human experimentation (Health Research Authority, UK) and with the Helsinki Declaration of 1975, as revised in 2008. Ethics approval was obtained via Health Research Authority (references 243037 and 279980) and Research Ethics Committee (references 18/LO/1936 and 20/YH/0223). Participants consented to participating in the study in line with Declaration of Helsinki on Good Clinical Practice.

## ORCID iD

Leon Jonker  <https://orcid.org/0000-0001-5867-4663>

## Supplemental material

Supplemental material for this article is available online.

## References

- Public Health England. Sexually transmitted infections and screening for chlamydia in England. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/1015176/STI\\_NCSP\\_report\\_2020.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1015176/STI_NCSP_report_2020.pdf) (2020, accessed 22 August 2022).
- Fifer H, Saunders J, Soni S, et al. 2018 UK National guideline for the management of infection with *Neisseria gonorrhoeae*. *Int J STD AIDS* 2020; 31: 4–15.
- Public Health England. Guidance for the detection of gonorrhoea in England. Available from: [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/972388/Guidance\\_for\\_the\\_detection\\_of\\_gonorrhoea\\_in\\_England\\_2021.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/972388/Guidance_for_the_detection_of_gonorrhoea_in_England_2021.pdf), (accessed 10 October 2022).
- Lin EY, Adamson PC and Klausner JD. Epidemiology, treatments, and vaccine development for antimicrobial-resistant *Neisseria gonorrhoeae*: current strategies and future directions. *Drugs* 2021; 81: 1153–1169.
- World Health Organization. Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022–2030. Available from: <https://reliefweb.int/report/world/global-health-sector-strategies-respectively-hiv-viral-hepatitis-and-sexually-transmitted-infections-period-2022-2030-enarruzh>, (accessed 10 October 2022).
- Clarke E, Patel C, Patel R. European Collaborative Clinical Group (ECCG), et al. The 2018–19 International union against sexually transmitted infections European collaborative clinical group report on the diagnosis and treatment of gonorrhoea in Europe. *Int J STD AIDS* 2020; 31: 77–81.
- Thompson DS and French SA. Comparison of commercial Amies transport systems with in-house amies medium for recovery of *Neisseria gonorrhoeae*. *J Clin Microbiol* 2011; 37(9): 3020–3021.
- Alexander S. The challenges of detecting gonorrhoea and chlamydia in rectal and pharyngeal sites: could we, should we, be doing more? *Sex Transm Infect* 2009; 85: 159–160.
- Verma R and Sood S. Gonorrhoea diagnostics: an update. *Indian J Med Microbiol* 2016; 34(2): 139–145.
- Farhat SE, Thibault M and Devlin R. Efficacy of swab transport system in maintaining viability of *Neisseria gonorrhoeae* and *Streptococcus pneumoniae*. *J Clin Microbiol* 2001; 39(8): 2958–2960.
- Gizzie N and Adukwu E. Evaluation of liquid-based swab transport systems against the new approved CLSI M40-A2 Standard. *J Clin Microbiol* 2016; 54(4): 1152–1156.
- Public Health England. UK standards for microbiology investigations. [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment\\_data/file/444199/ID\\_6i3.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/444199/ID_6i3.pdf), (accessed 10 October 2022).
- Sng EH, Rajan VS, Yeo KL, et al. The recovery of *Neisseria gonorrhoeae* from clinical specimens: effects of different temperatures, transport times, and media. *Sex Trans Dis* 1982; 9: 74–78.
- Paris KS, Font B, Mehta SR, et al. 72-Hour transport recovery of antimicrobial resistant *Neisseria gonorrhoeae* isolates using the InTray® GC method. *Plos One* 2022; 17(1): e0259668.
- Beverly A, Bailey-Griffin JR and Schwebke JR. InTray GC medium versus modified Thayer-Martin agar plates for diagnosis of gonorrhea from endocervical specimens. *J Clin Microbiol* 2000; 38(10): 3825–3826.
- Stoltey J, Cohen S, Gose S, et al. Performance of the InTray GC system versus modified thayer-martin agar for diagnosis of urethral gonorrhea. *InOpen Forum Infect Dis* 2015; 2(suppl\_1): 994.
- Bachmann LH, Johnson RE, Cheng H, et al. Nucleic acid amplification tests for diagnosis of *Neisseria gonorrhoeae* and Chlamydia trachomatis rectal infections. *J Clin Microbiol* 2010; 48(5): 1827–1832.
- Skulskal E, Młynarczyk-Bonikowska B, Walter de Walthoffen S, et al. The comparison of real-time NAAT and bacterial culture in laboratory diagnostics of gonorrhoea in patients of department of dermatology and venereology medical University of Warsaw. *Med Dosw Mikrobiol* 2015; 67(1): 29–38.
- Vyth R, Leval A, Eriksson B, et al. Gonorrhoea diagnostic and treatment uncertainties: risk factors for culture negative confirmation after positive nucleic acid amplification tests. *Plos One* 2016; 11(5): e0155017. DOI: [10.1371/journal.pone.0155017](https://doi.org/10.1371/journal.pone.0155017).
- Brook G. The performance of non-NAAT point-of-care (POC) tests and rapid NAAT tests for chlamydia and gonorrhoea infections. An assessment of currently available assays. *Sex Transm Infect* 2015; 91(8): 539–544.
- Priest D, Ong JJ, Chow EP, et al. *Neisseria gonorrhoeae* DNA bacterial load in men with symptomatic and asymptomatic gonococcal urethritis. *Sex Transm Infect* 2017; 93(7): 478–481.
- Evans KD, Peterson EM, Curry JI, et al. Effect of holding temperature on isolation of *Neisseria gonorrhoeae*. *J Clin Microbiol* 1986; 24(6): 1109–1110.